Turnover: 526 million EUR (2023)

Country: France

LFB is a biopharmaceutical group that develops, manufactures and markets blood-derived medicinal products and recombinant proteins for the treatment of patients suffering from serious pathologies.founded in 1994 in France, LFB is today one of the leading European players offering plasma-derived medicinal products to healthcare professionals, with a mission to provide patients with new treatment options in three major therapeutic areas. LFB currently markets 15 products in more than 30 countries, and more than 2,500 employees in France and around the world are committed to the company's mission every day

News

Biomedicaments : LFB Biomanufacturing doubles its production capacity in Alès 06/10/2023

  • LFB Biomanufacturing has announced a €20 million investment in Alès, in the Gard region of France.
  • LFB Biomanufacturing produces a recombinant drug from rabbit milk protein. 50% of pharmaceutical products under development are biomedicines.
  • LFB Biomanufacturing has two 1,000-liter bioreactors. They plan to acquire six 2,000-liter single-use bioreactors, including two as part of this investment.
  • The company plans to recruit 50 new employees by 2026, bringing its total workforce to 125.
  • The LFB Biomanufacturing site, established 27 years ago, is approved by the US Food and Drug Administration.
  • The LFB group, based in Les Ulis (Essonne), has sales of 524 million euros in 2022 and employs 2,600 people.
  • A plant under construction in Arras (Pas-de-Calais).

Pharmaceuticals: French public laboratory LFB to cut 120 jobs" 06/02/2019

  • The French public laboratory LFB is cutting 120 jobs out of 1,800 in France (2,300 in total).
  • LFB has held exclusive rights to fractionate plasma from blood donations for 24 years.
  • The group will refocus on plasma-derived medicinal products and recombinant proteins.
  • LFB will withdraw from the Brazilian and Middle Eastern markets.
  • The group's sales were €497 million in 2017 and €516 million in 2016.
  • ANSM notes several deviations in LFB's industrial process.
  • The group expects an 18% drop in sales in 2018, estimated at around 400 million euros.

Studies mentioning this company

The bioanalysis market - France

Other companies mentioned:

  • Eurofins
  • Carso groupe
  • Mérieux NutriSciences
  • SGS
  • Intertek
  • Bureau Veritas BV
  • Phytocontrol
  • Qualtech (IFBM Groupe)
  • Valbiotis
  • Abbott Groupe
  • Agilent Technologies
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Genomic Vision
  • LFB Groupe
  • Novacyt
  • Qiagen
  • Randox Laboratories
  • Roche Diagnostics France (Roche Group)
  • Thermo Fisher Diagnostics